DPDPE vs Somatostatin
Head-to-head comparison of DPDPE ([D-Pen2, D-Pen5]-enkephalin) and Somatostatin (Somatostatin-14) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | DPDPE | Somatostatin |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | [D-Pen2, D-Pen5]-enkephalin | Somatostatin-14 |
| Molecular Weight | 645.79 Da | 1637.85 |
| Half-Life | 15-60 minutes in plasma | 1-3 min |
| Amino Acids | 5 | 14 |
| Typical Dose | 0.01-1 ug per animal | N/A|N/A |
| Route | Intrathecal / intracerebroventricular | IV/SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 800 | 84 |
| Research Status | Pre-clinical | Approved |
DPDPE Benefits
- ✓delta-opioid selectivity
- ✓improved conformational stability
- ✓analgesic receptor mapping
- ✓useful in chronic pain models
Somatostatin Benefits
- ✓nociceptive inhibition
- ✓anti-inflammatory signaling
- ✓visceral pain modulation
DPDPE Dosing
Intrathecal 0.01-1 ug per animal|Intracerebroventricular 0.01-0.5 ug per animal|In vitro 0.1-20 nM
Somatostatin Dosing
N/A|N/A
DPDPE Side Effects
- ⚠sedation
- ⚠nausea-like opioid effects
- ⚠tolerance with repeated dosing
Somatostatin Side Effects
- ⚠hyperglycemia
- ⚠bradycardia
- ⚠GI upset
Research Overview
DPDPE
DPDPE is widely cited in opioid pharmacology because it helped establish the functional role of delta-opioid receptors in pain control. Its constrained structure is also used to explore how peptide cyclization changes potency, stability, and tissue selectivity.
Somatostatin
Somatostatin reduces release of multiple excitatory mediators and can suppress pain signaling in preclinical and limited translational work. Its analgesic use is not standard, but the peptide is real and mechanistically relevant to pain control.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.